Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)

Carlo Lazzaro, Riccardo Bartoletti, Giorgio Guazzoni, Fausto Orestano, Giovanni L. Pappagallo, Domenico Prezioso, Filiberto Zattoni

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The paper compares costs and Quality-Adjusted Life Years (QALYs) of differ ent hormonal therapies (HTs) administered to 275 out of 471 patients with prostate can cer (PC) enrolled in the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS), who did not change HT during the study period. Methods: QALYs and costs related to monoHT with: cyproterone acetate (CYP) (42 patients); bicalutamide (BIC) (41 patients); LHRH-a (96 patients) and complete androgenic block ade (CAB) with: CYP (CYP CAB) (50 patients); BIC (BIC CAB) (46 patients) were compared via a cost-utility analysis (CUA) adopting the Italian National Healthcare Service (INHS) viewpoint. Results: As no statistical significant difference among the mean QALYs gained with the different HTs was detected (p = 0.116), CUA was replaced by a cost minimization analysis (CMA). However, the lowest and the highest mean QALYs gained per patient were registered for BIC CAB (0.59; 95% CI: 0.50; 0.68) and for for CYP (0.75; 95% CI: 0.68; 0.82), respectively. CYP was the least costly HT, reaching the lowest and the highest savings when compared to LHRH-a (-Euros 974.99; 95% CI: -Euros 1066.86; -Euros 883.12; p

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalArchivio Italiano di Urologia e Andrologia
Volume79
Issue number3
Publication statusPublished - Sep 2007

Keywords

  • Cost-minimization analysis
  • Cyproterone acetate
  • Prostate cancer
  • QuABIOS

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)'. Together they form a unique fingerprint.

Cite this